Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations.

This work presents a new dry powder system consisting of microencapsulated protein-loaded chitosan nanoparticles (CS NPs). The developed system was evaluated in vivo in rats in order to investigate its potential to transport insulin (INS), a model protein, to the deep lung, where it is absorbed into systemic circulation. The INS-loaded CS NPs were prepared by ionotropic gelation and characterized for morphology, size, zeta potential, association efficiency and loading capacity. Afterwards, the NPs were co-spray dried with mannitol resulting in a dry powder with adequate aerodynamic properties for deposition in deep lungs. The assessment of the plasmatic glucose levels following intratracheal administration to rats revealed that the microencapsulated INS-loaded CS NPs induced a more pronounced and prolonged hypoglycemic effect compared to the controls. Accordingly, the developed system constitutes a promising alternative to systemically deliver therapeutic macromolecules to the lungs, but it can also be used to provide a local effect.

[1]  Y. Kawashima,et al.  Mucoadhesive nanoparticulate systems for peptide drug delivery. , 2001, Advanced drug delivery reviews.

[2]  Simon Cawthorne,et al.  Particle engineering techniques for inhaled biopharmaceuticals. , 2006, Advanced drug delivery reviews.

[3]  S. Giosué,et al.  Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. , 2000, European cytokine network.

[4]  N. He,et al.  Chitosan/sodium tripolyphosphate nanoparticles: preparation, characterization and application as drug carrier. , 2009, Journal of biomedical nanotechnology.

[5]  C. Remuñán-López,et al.  Microencapsulated chitosan nanoparticles for lung protein delivery. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  V. Préat,et al.  Confocal imaging of rat lungs following intratracheal delivery of dry powders or solutions of fluorescent probes. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[7]  K. Amighi,et al.  Formulation strategy and use of excipients in pulmonary drug delivery. , 2010, International journal of pharmaceutics.

[8]  M. Alonso,et al.  Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. , 2007, International journal of pharmaceutics.

[9]  A. Misra,et al.  A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: A technical note , 2005, AAPS PharmSciTech.

[10]  Wei Yang,et al.  Inhaled nanoparticles--a current review. , 2008, International journal of pharmaceutics.

[11]  E. Crandall,et al.  Hydrophilic solute transport across rat alveolar epithelium. , 1989, Journal of applied physiology.

[12]  J. Patton,et al.  Mechanisms of macromolecule absorption by the lungs , 1996 .

[13]  V. Cardile,et al.  Chitosan microspheres for intrapulmonary administration of moxifloxacin: interaction with biomembrane models and in vitro permeation studies. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  Y Ikada,et al.  Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. , 1988, Biomaterials.

[15]  Yu Zhang,et al.  Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. , 2004, International journal of pharmaceutics.

[16]  Qun Wang,et al.  Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery. , 2009, Journal of biomedical nanotechnology.

[17]  J. Evans,et al.  The distribution of dust in the rat lung following administration by inhalation and by single intratracheal instillation. , 1985, Environmental research.

[18]  Monireh Jalalipour,et al.  Effect of dimethyl-beta-cyclodextrin concentrations on the pulmonary delivery of recombinant human growth hormone dry powder in rats. , 2008, Journal of pharmaceutical sciences.

[19]  B. Forbes,et al.  In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate , 2001, AAPS PharmSciTech.

[20]  H Salem,et al.  Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[21]  G. P. Martin,et al.  Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  R. Löbenberg,et al.  Targeted delivery of nanoparticles for the treatment of lung diseases. , 2008, Advanced drug delivery reviews.

[23]  Véronique Préat,et al.  Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[24]  G. van Amerongen,et al.  Administration of an insulin powder to the lungs of cynomolgus monkeys using a Penn Century insufflator. , 2004, International journal of pharmaceutics.

[25]  H. Junginger,et al.  Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[26]  C. Remuñán-López,et al.  Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles , 1999, Pharmaceutical Research.

[27]  Kyle E Broaders,et al.  In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. , 2010, Molecular pharmaceutics.

[28]  H. Folkesson,et al.  Mechanisms of alveolar protein clearance in the intact lung. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[29]  O. Raabe,et al.  Factors influencing the deposition of inhaled particles. , 1976, Environmental health perspectives.

[30]  A. Bernkop‐Schnürch,et al.  Oral peptide drug delivery: polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro. , 2000, Biomaterials.

[31]  J. Kaur,et al.  Inhalable microparticles containing large payload of anti-tuberculosis drugs. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[32]  Shohei Sugimoto,et al.  Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[33]  de las Nieves FJ,et al.  Colloidal Stability of Polymer Colloids with Variable Surface Charge. , 1999, Journal of colloid and interface science.

[34]  P. Garidel,et al.  Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[35]  J. S. Lobo,et al.  Effect of hydroxypropyl methylcellulose and hydrogenated castor oil on naproxen release from sustained-release tablets , 2001, AAPS PharmSciTech.

[36]  A. Clark,et al.  Design of fine particles for pulmonary drug delivery , 2007, Expert opinion on drug delivery.

[37]  N. Rooijen,et al.  The macrophage as target or obstacle in liposome-based targeting strategies , 1998 .

[38]  J. Hanes,et al.  Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[39]  M. Davies,et al.  The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers. , 2008, International journal of pharmaceutics.

[40]  Fakhrul Ahsan,et al.  Absorption enhancers in pulmonary protein delivery. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[41]  C. Remuñán-López,et al.  Chitosan nanoparticle-loaded mannitol microspheres: structure and surface characterization. , 2007, Biomacromolecules.

[42]  V. Préat,et al.  Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[43]  I. El-Sherbiny,et al.  Swellable microparticles as carriers for sustained pulmonary drug delivery. , 2010, Journal of pharmaceutical sciences.

[44]  Waseem Kaialy,et al.  Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler. , 2010, Colloids and surfaces. B, Biointerfaces.

[45]  J. Brain Inhalation, deposition, and fate of insulin and other therapeutic proteins. , 2007, Diabetes technology & therapeutics.

[46]  M. L. La Rotonda,et al.  Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[47]  Lawrence X. Yu,et al.  In Vitro Considerations to Support Bioequivalence of Locally Acting Drugs in Dry Powder Inhalers for Lung Diseases , 2009, The AAPS Journal.

[48]  K. Juni,et al.  Pulmonary Delivery of Salmon Calcitonin Dry Powders Containing Absorption Enhancers in Rats , 2004, Pharmaceutical Research.

[49]  S. Anderson,et al.  Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction. , 2010, Respiratory medicine.

[50]  M. Welham,et al.  Spray‐dried insulin particles retain biological activity in rapid in‐vitro assay , 2001, The Journal of pharmacy and pharmacology.

[51]  J. Birchall,et al.  Chitosan-Modified Dry Powder Formulations for Pulmonary Gene Delivery , 2006, Pharmaceutical Research.

[52]  R. Pandey,et al.  Antitubercular inhaled therapy: opportunities, progress and challenges. , 2005, Journal of Antimicrobial Chemotherapy.

[53]  J. Thipphawong,et al.  Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosis. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[54]  E. Daviskas,et al.  Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. , 2008, International journal of pharmaceutics.

[55]  M. Davis,et al.  Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. , 1976, Environmental research.

[56]  M. Alonso,et al.  Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines , 1997, Pharmaceutical Research.

[57]  P. Artursson,et al.  Chitosan and the mucosal delivery of biotechnology drugs. , 2005, Drug discovery today. Technologies.